Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Update

Kura Oncology, Inc. (NASDAQ:KURA) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 10,440,000 shares, a growth of 17.4% from the December 15th total of 8,890,000 shares. Currently, 16.0% of the shares of the stock are short sold. Based on an average trading volume of 1,660,000 shares, the short-interest ratio is presently 6.3 days.

Analyst Ratings Changes

KURA has been the topic of several analyst reports. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Scotiabank cut their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Finally, JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $27.38.

Institutional Trading of Kura Oncology

Hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in shares of Kura Oncology during the third quarter worth $25,000. Point72 DIFC Ltd bought a new stake in Kura Oncology during the 3rd quarter worth $146,000. Quarry LP acquired a new position in Kura Oncology in the 2nd quarter worth about $196,000. Erste Asset Management GmbH bought a new position in Kura Oncology in the third quarter valued at about $215,000. Finally, Bellevue Group AG boosted its stake in shares of Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after purchasing an additional 3,600 shares in the last quarter.

Kura Oncology Price Performance

KURA opened at $7.26 on Friday. The company’s 50 day moving average is $10.51 and its 200-day moving average is $16.36. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.